Search

Search results

Homepage

Logos for the group of charities involved in the joint statement

Joint statement on benefits and employment support

As a coalition of sight loss charities, we are calling on the Government to make the benefit system and employment support fit for purpose for blind and partially sighted people.

News

A man and a woman wearing smart clothes playing table tennis

How we can work together

We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.

The text in graphic says: Eye care support pathway Supporting you at every stage of your journey Underneath a graphic shows the four stages of an individual’s journey with the following text: 1. Having my initial appointment 2. Waiting well 3. Having my diagnosis confirmed 4. Waiting well 5. Support after my diagnosis 6. Waiting well 7. Living well with my condition Underneath this graphic it outlines what an individual can expect on their journey. Understand my eye care journey Understand my diagnosis Access emotional and practical support

New Eye Care Support Pathway wins cross-sector backing

New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.

News

e-Newsletter January 2024

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

Webinar: Influencing with Retina UK

The latest webinar from Retina UK.

Some multi-coloured Easter eggs.

Easter Fundraising

If you could use the long bank holiday weekend to fundraise for Retina UK, we would love to hear from you!

Retina UK Raffle – Terms and Conditions

Taking part in the 2021 Virtual London Marathon

Caryn talks about her experience taking part in the 2021 Virtual London Marathon.

News

Gene Therapy improves functional measures in XLRP

Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.